These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25225364)

  • 21. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
    Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
    J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model.
    Machida Y; Nakagawa M; Matsunaga H; Yamaguchi M; Ogawara Y; Shima Y; Yamagata K; Katsumoto T; Hattori A; Itoh M; Seki T; Nishiya Y; Nakamura K; Suzuki K; Imaoka T; Baba D; Suzuki M; Sampetrean O; Saya H; Ichimura K; Kitabayashi I
    Mol Cancer Ther; 2020 Feb; 19(2):375-383. PubMed ID: 31727689
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation.
    Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD
    Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
    Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
    Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
    Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
    Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.
    Borodovsky A; Salmasi V; Turcan S; Fabius AW; Baia GS; Eberhart CG; Weingart JD; Gallia GL; Baylin SB; Chan TA; Riggins GJ
    Oncotarget; 2013 Oct; 4(10):1737-47. PubMed ID: 24077805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.
    Rohle D; Popovici-Muller J; Palaskas N; Turcan S; Grommes C; Campos C; Tsoi J; Clark O; Oldrini B; Komisopoulou E; Kunii K; Pedraza A; Schalm S; Silverman L; Miller A; Wang F; Yang H; Chen Y; Kernytsky A; Rosenblum MK; Liu W; Biller SA; Su SM; Brennan CW; Chan TA; Graeber TG; Yen KE; Mellinghoff IK
    Science; 2013 May; 340(6132):626-30. PubMed ID: 23558169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MiR-148a increases glioma cell migration and invasion by downregulating GADD45A in human gliomas with IDH1 R132H mutations.
    Cui D; Sajan P; Shi J; Shen Y; Wang K; Deng X; Zhou L; Hu P; Gao L
    Oncotarget; 2017 Apr; 8(15):25345-25361. PubMed ID: 28445981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH1(R132H) mutation increases U87 glioma cell sensitivity to radiation therapy in hypoxia.
    Wang XW; Labussière M; Valable S; Pérès EA; Guillamo JS; Bernaudin M; Sanson M
    Biomed Res Int; 2014; 2014():198697. PubMed ID: 24895549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.
    Lu VM; McDonald KL
    CNS Oncol; 2018 Jan; 7(1):41-50. PubMed ID: 29303363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
    Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
    Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating Mechanisms of IDH1 Regulation through Site-Specific Acetylation Mimics.
    Weeks J; Strom AI; Widjaja V; Alexander S; Pucher DK; Sohl CD
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34065652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
    Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
    Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H.
    Stoczynska-Fidelus E; Och W; Rieske P; Bienkowski M; Banaszczyk M; Winiecka-Klimek M; Zieba J; Janik K; Rosiak K; Treda C; Stawski R; Radomiak-Zaluska A; Piaskowski S
    Anticancer Res; 2014 Jun; 34(6):2859-67. PubMed ID: 24922649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
    Zhao S; Lin Y; Xu W; Jiang W; Zha Z; Wang P; Yu W; Li Z; Gong L; Peng Y; Ding J; Lei Q; Guan KL; Xiong Y
    Science; 2009 Apr; 324(5924):261-5. PubMed ID: 19359588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
    Capper D; Weissert S; Balss J; Habel A; Meyer J; Jäger D; Ackermann U; Tessmer C; Korshunov A; Zentgraf H; Hartmann C; von Deimling A
    Brain Pathol; 2010 Jan; 20(1):245-54. PubMed ID: 19903171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
    Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
    Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.